Kiniksa Pharmaceuticals, Ltd (KNSA)

Etorro trading 970x250
Kiniksa Pharmaceuticals, Ltd (KNSA) Logo

About Kiniksa Pharmaceuticals, Ltd

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company’s preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda. Address: Clarendon House, Hamilton, Bermuda, HM 11

Kiniksa Pharmaceuticals, Ltd News and around…

Latest news about Kiniksa Pharmaceuticals, Ltd (KNSA) common stock and company :

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
05 May, 2022 Yahoo! Finance

Kiniksa Pharmaceuticals, Ltd. ( NASDAQ:KNSA ) came out with its first-quarter results last week, and we wanted to see...

Recap: Kiniksa Pharmaceuticals Q1 Earnings
03 May, 2022 FinancialContent

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
03 May, 2022 Yahoo! Finance

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.77% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
02 May, 2022 Yahoo! Finance

HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. Eastern Time to report its first quarter 2022 financial results and corporate activities. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately

Noteworthy Wednesday Option Activity: KNSA, BW, NVAX
20 Apr, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Kiniksa Pharmaceuticals Ltd (KNSA), where a total volume of 1,222 contracts has been traded thus far today, a contract volume which is representative of approximately 122,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54% of KNSA's average daily trading volume over the past month, of 226,400 shares..

The past three years for Kiniksa Pharmaceuticals (NASDAQ:KNSA) investors has not been profitable
13 Apr, 2022 Yahoo! Finance

As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...

Notable Monday Option Activity: VIRX, GM, KNSA
14 Mar, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Viracta Therapeutics Inc (VIRX), where a total of 1,734 contracts have traded so far, representing approximately 173,400 underlying shares. That amounts to about 68.6% of VIRX's average daily trading volume over the past month of 252,915 shares..

Huadong Strikes $1 Billion Deal for Asia Rights to Four ADC Candidates
28 Feb, 2022 FinancialContent

Huadong Medicine will acquire Asia rights (ex-Japan) for two Heidelberg Pharma ADC candidates with options on two more in a deal potentially worth more than $1 billion. The drug rights are worth up to $930 million while Huadong will also purchase 35% of Heidelberg for $118 million. Huadong, which will make a $20 million upfront payment to Heidelberg, is very busy on the deal front currently: last week it entered a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in Southeast Asia. More details.... Stock Symbols: (SHZ: 0963) (FSE: HPHA) (NSDQ: KNSA) Share this with colleagues:

Week In Review: Huadong Pharma Enters $662 Million Deal For Two Kiniksa Anti-Inflammatory Drugs
26 Feb, 2022 FinancialContent

Huadong Pharma announced a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in southeast Asia (ex-Japan). Huadong will pay $22 million and be responsible for up to $640 million in milestones, plus royalties.

Kiniksa Pharma, Huadong Medicine Ink Licensing Pact For Arcalyst, Mavrilimumab
22 Feb, 2022 FinancialContent

Kiniksa Pharmaceuticals Ltd(NASDAQ: KNSA) and Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd., a subsidiary ofHuadong ...

Kiniksa Pharmaceuticals: Q4 Earnings Insights
22 Feb, 2022 FinancialContent

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported its Q4 earnings results on Tuesday, February 22, 2022 at 08:00 ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates
22 Feb, 2022 Yahoo! Finance

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -20.45% and 14.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
22 Feb, 2022 Yahoo! Finance

– ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 –– ARCALYST collaboration achieved profitability in Q4 2021 –– ARCALYST full-year 2022 net revenue expected to be $115 - $130 million –– Strategic collaboration with Huadong Medicine to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific Region (excluding Japan) –– Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Kiniksa P

Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
22 Feb, 2022 Yahoo! Finance

– Collaboration includes rights to develop and commercialize ARCALYST® and mavrilimumab in the Asia Pacific Region (excluding Japan) – – Kiniksa to receive $22 million upfront; eligible to receive development and commercial milestone payments and tiered royalties – HAMILTON, Bermuda, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of disea

Earnings Scheduled For February 22, 2022
22 Feb, 2022 FinancialContent

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per ...

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
18 Feb, 2022 Yahoo! Finance

HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2021 financial results and corporate update. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website wit

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
11 Jan, 2022 FinancialContent

Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market ...

Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones
10 Jan, 2022 Yahoo! Finance

- ARCALYST® full-year 2022 guidance to be provided with Q4 2021 financial results -- Vixarelimab Phase 2b data in prurigo nodularis expected in 2H 2022 –- KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients -- Year-end 2021 cash reserves expected to fund current operating plan into 2024 - HAMILTON, Bermuda, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of assets designed to modulat

Sum Up The Pieces: XBI Could Be Worth $206
07 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $205.52 per unit.

Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
03 Jan, 2022 Yahoo! Finance

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) In A Good Position To Deliver On Growth Plans?
03 Jan, 2022 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Wall Street Analysts See a 151% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?
31 Dec, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 150.6% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Company News for Dec 29, 2021
29 Dec, 2021 Yahoo! Finance

Companies in The News Are: KNSA,AAPL,VIPS,CCL

10 Biggest Price Target Changes For Wednesday
29 Dec, 2021 FinancialContent

Tigress Financial lifted the price target on McDonald's Corporation (NYSE: MCD) from $271 to $314. McDonald's shares fell ...

Why Kiniksa Pharmaceuticals Stock Is Falling Today
28 Dec, 2021 FinancialContent

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) is trading lower Tuesday morning afterthe company announced the Phase 3 trial of ...

Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
28 Dec, 2021 Yahoo! Finance

HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the Phase 3 portion of the Phase 2/3 trial of mavrilimumab in COVID-19-related acute respiratory syndrome (ARDS) did not meet the primary efficacy endpoint. Mavrilimumab is an investigational fully human monoclonal antibody that targets g

Kiniksa Pharmaceuticals Down After Phase 3 Trial Fails to Meet Endpoint
28 Dec, 2021 Yahoo! Finance

By Sam Boughedda

Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
01 Dec, 2021 Yahoo! Finance

Kiniksa Pharmaceuticals, Ltd. (KNSA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference
23 Nov, 2021 Yahoo! Finance

HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 12:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within appro

Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 138% to Reach the Level Wall Street Analysts Expect?
19 Nov, 2021 Yahoo! Finance

The consensus price target hints at a 137.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Kiniksa Pharmaceuticals, Ltd (KNSA) is a NASDAQ Common Stock listed in , ,

970x250